Scientists can be powerful influencers and role models. So there’s reason for concern when the same names and faces dominate coverage and visibility.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Myriad Genetics has revealed it is acquiring genetic screening firm Counsyl for $375 million.
J. Craig Venter shared on Twitter last week that he is retiring from Human Longevity, and returning to the J. Craig Venter Institute (JCVI) to continue his work.
Start-up X Genomics has revealed its X Genomics Human Variant Genome Project, which aims to bring together genome specialists to build a genetic data chain powered by the blockchain.
Takeda is beginning to trim down its business and looking to bring in some much-needed cash to pull in the Shire acquisition.
The Cleveland Clinic and Brooks Automation have said they are launching a 21,000 square foot biorepository in Cleveland’s Fairfax neighbourhood to improve researchers’ study of human tissue samples and advance personalised medicine.
Illumina has revealed that it has acquired Edico Genome, with the intention of building on the solid foundation of DRAGEN, to deliver a more streamlines sample for customers.
Medigene has agreed to expand its nearly two-year-old strategic alliance with Bluebird bio, focusing on the research and development of T-cell receptor-modified T-cell immunotherapies (TCR-T) for the treatment of cancer.
The funds will be used to support the next phase in creating Luna DNA’s genomic and medical research platform and enlisting data contributors.
Under the settlement agreement, Oxford Nanopore will refrain from offering its 2D sequencing products in the UK and Germany through the end of 2023.
Researchers are trying to boost the effectiveness of cancer-killing viruses to treat conditions, including brain tumours.